Opinion|Videos|June 27, 2024

Biomarker Testing and Guideline-Recommended Care in mNSCLC

Mark Socinski, MD, introduces a panel of medical experts as they kick off a discussion surrounding biomarker testing and guideline recommendations in the metastatic non-small cell lung cancer treatment landscape.

Video content above is prompted by the following:

  • What are the current NCCN guideline recommendations regarding molecular/genetic testing (NGS, etc.) for newly diagnosed mNSCLC patients?
  • Do the NCCN guideline recommendations for molecular/genetic testing and biomarker evaluation differ between squamous and non-squamous non-small cell lung cancer? If so, how, and why?
  • What is the rationale and clinical utility of comprehensive biomarker testing in this setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo